The invention relates to radially expandable endoprostheses which are adapted to be implanted in a lumen of a tubular organ. An “endoprosthesis”, or stent, corresponds to an artificial implantable medical device that is placed inside the body. A “lumen” refers to a cavity of a tubular organ such as a blood vessel. A stent is an example of these endoprostheses. Stents are generally cylindrically shaped devices which function to hold open and sometimes expand a segment of a blood vessel or other anatomical lumens such as urinary tracts and bile ducts. Stents are often used in the treatment of atherosclerotic stenosis in blood vessels. “Stenosis” refers to a narrowing or constriction of the diameter of a bodily passage or orifice. In such treatments, stents reinforce vessels and prevent restenosis following angioplasty in the vascular system. “Restenosis” refers to the reoccurrence of stenosis in a blood vessel or heart valve after it has been treated (as by balloon angioplasty or valvuloplasty) with apparent success.
A treatment involving a stent includes both delivery and deployment of the stent. “Delivery” refers to introducing and transporting the stent through a lumen of a tubular organ to a region requiring treatment. “Deployment” corresponds to the expanding of the stent within the lumen at the treatment region. Delivery and deployment of a stent may be accomplished by positioning the stent about one end of a catheter, inserting the end of the catheter through the skin into the lumen, advancing the catheter in the lumen to a desired treatment location, expanding the stent at the treatment location, and then removing the catheter from the lumen. In the case of a balloon expandable stent, the stent is mounted about a balloon disposed on the catheter. Mounting the stent typically involves compressing or crimping the stent onto the balloon. The stent is then expanded by inflating the balloon. The balloon may then be deflated and the catheter withdrawn. In the case of a self-expanding stent, the stent may be secured to the catheter via a retractable sheath or a sock. When the stent is in a desired bodily location, the sheath may be withdrawn allowing the stent to self-expand.
Stents have been made of many materials including metals and polymers. Polymer materials include both nonbioerodable and bioerodable plastic materials. In some applications, a polymeric bioerodable stent may be more advantageous than a metal stent due to its biodegradeability and increased flexibility relative to the metal stent. The cylindrical structure of a stent is typically composed of a scaffolding that includes a pattern or network of interconnecting structural elements or struts. The scaffolding can be formed from wires, tubes, or planar films of material rolled into a cylindrical shape. In addition, a medicated stent may be fabricated by coating the surface of either a metallic or polymeric scaffolding with a polymeric carrier. The polymeric carrier can include an active agent or drug. Furthermore, the pattern that makes up the stent allows the stent to be radially expandable and longitudinally flexible. Longitudinal flexibility facilitates delivery of the stent and rigidity is needed to hold open a lumen of a tubular organ. Generally, the pattern should be designed to maintain the longitudinal flexibility and rigidity required of the stent. The stent should also have adequate strength in the circumferential direction.
A number of techniques have been suggested for the fabrication of stents from tubes and planar films or sheets. One such technique involves laser cutting or etching a pattern onto a material. Laser cutting may be performed on a planar film of a material which is then rolled into a tube. Alternatively, a desired pattern may be etched directly onto a tube. Other techniques involve cutting a desired pattern into a sheet or a tube via chemical etching or electrical discharge machining. Laser cutting of stents has been described in a number of publications including U.S. Pat. No. 5,780,807 to Saunders, U.S. Pat. No. 5,922,005 to Richter and U.S. Pat. No. 5,906,759 to Richter.
In a typical method of manufacturing a metal stent with a laser, a mandrel is placed inside the lumen of metal tubing. A “mandrel” refers to a metal bar or rod on which an implantable medical device may be shaped. The mandrel provides structural support to the tubing as it is being cut and shaped. See, e.g., U.S. Pat. No. 5,780,807 to Saunders.
Methods for the manufacture of polymeric implantable medical devices, such as stents, using a mandrel in the manufacturing process thereof are disclosed.
According to one form of a method, a polymeric mandrel may be employed to manufacture a polymeric stent. Thus, a polymeric tube is positioned on a mandrel of a stent manufacturing device and the positioned tube is cut, etched or otherwise worked on to form a polymeric stent. A laser may be used to etch the polymeric tubing mounted on the polymeric mandrel to form the polymeric stent. The mandrel may provide shielding protection to the inner diameter of the polymeric tubing reducing damage caused by the high intensity laser in the form of angled cuts, or “nicks,” typical in non-mandrel polymer stent manufacturing processes.
According to another form of a method, a method of manufacturing an implantable medical device includes: positioning at least one of a polymeric mandrel or polymeric tubing relative to the other such that the polymeric mandrel is within the polymeric tubing, forming a tubing-mandrel fixture; positioning the tubing-mandrel fixture between two locking mechanisms of a stent manufacturing device; and lasing the polymeric tube to form an implantable medical device.
In some embodiments, a polymeric implantable medical device may be formed by the process of positioning at least one of a polymeric mandrel or polymeric tubing relative to the other such that the polymeric mandrel is within the polymeric tubing, forming a mandrel-tubing fixture and, after the positioning, cutting the polymeric tubing with a laser to form an implantable medical device.
In some embodiments, the polymeric mandrel may be of the same polymeric material as that of the polymeric stent or may be coated with the same polymeric material as that of the polymeric stent. In some embodiments, the polymeric materials of the polymeric mandrel and the polymeric stent may differ. Because the polymeric mandrel is composed of or coated with a material the same as or substantially the same as the material of the polymeric stent, the resultant polymeric stent may be completely or substantially free of undesirable particulate contaminates in contrast to processes in which a metal or glass mandrel is used.
Other objects and advantages of the present invention will become more apparent to those persons having ordinary skill in the art to which the present invention pertains from the foregoing description taken in conjunction with the accompanying drawings.
A polymeric stent may be manufactured by a variety of methods. In one method, the polymeric stent may be formed by laser cutting a flat polymeric sheet in the form of rings and links, and then subsequently rolling the pattern into the shape of the cylindrical stent and providing a longitudinal weld to form the stent. In another method, a flat polymeric sheet may be chemically etched and then subsequently rolled and welded to form the polymeric stent. Additionally, a polymeric wire may be coiled to form a polymeric stent. In yet another method, a polymeric stent may be formed from a tube by laser cutting a pattern of cylindrical rings and connecting rings in the tube itself. See, e.g., U.S. Pat. No. 6,585,755 to Jackson et al.
In a conventional lasing process of manufacturing a polymeric stent from a tube, a mandrel may not typically be employed. Due to the retentive nature of polymeric materials for foreign particulates, a glass or metal mandrel may contaminate the polymeric stent if a laser beam from the laser strikes it and releases such contaminates. In other words, a glass mandrel may leave glass particulates, and a metal mandrel may leave large amounts of metal oxide contamination melted into the inner surface of the polymer stent, respectively. Such contaminants may cause adverse effects during and/or after the stent is implanted into the lumen of a bodily organ.
Non-use of a mandrel in the manufacturing process of a polymeric stent, however, may cause problems aside from contamination through use of glass or metal mandrels. It has been observed that in the manufacture of polymeric stents, damage to the inner surface of the stent can occur. The damage is typically in the form of at least one angled cut, or “nick”, within the inner surface area. The angled cuts are the result of the laser beam reaching the inner surface as the equal-but-opposite outer surface is being lased. The damage caused thereby may cause problems with delivery of the stent and/or adverse body reactions. This problem may be remedied by use of a typical mandrel (which may provide a shielding effect) in the manufacturing process; however, the problems associated with the use of metal or glass mandrels as described previously may result.
In the manufacturing process, a polymeric tube 8 may be mounted between support member 32′ and lock member 36′. The wall thickness of the polymeric tube 8 will typically vary throughout the tube body due to variations in the manufacturing process of polymeric tubes. A coaxial gas jet, rotary collet, tube support and beaming block apparatus of a laser (from hereonout abbreviated as a laser 100) may then be used for the etching process to form a polymeric stent 10′ from the polymeric tube 8. The laser 100 can include a laser beam 102, a focusing lens 104, a gas input 106, a coaxial gas jet assay 108 and a gas jet 110. A resultant polymeric stent 10′ manufactured using device 30′ is illustrated in
The manufacturing process as discussed in connection with
In
Support member 32 includes a flat end 50 that is coupled to a first end 52 of mandrel 34. In accordance to one embodiment, mandrel 34 can be permanently affixed to support member 32. Alternatively, support member 32 can include a bore 54 for receiving first end 52 of mandrel 34. First end 52 of mandrel 34 can be threaded to screw into bore 54. Alternatively, a non-threaded first end 52 of mandrel 34 can be press-fitted or friction-fitted within bore 54. Bore 54 should be deep enough so as to allow mandrel 34 to securely mate with support member 32. The depth of bore 54 can be over-extended so as to allow a significant length of mandrel 34 to penetrate the bore. This would allow the length of mandrel 34 to be adjusted to accommodate stents of various sizes.
Lock member 36 can include a flat end 56 that can be permanently affixed to a second end 58 of mandrel 34 if end 52 of mandrel 34 is disengagable from support member 32. A bore 54 extends along lock member 36 for allowing mandrel 34 to be in fluid communication with vacuum device 44. In accordance with another embodiment, mandrel 34 can have a threaded second end 58 for screwing into bore 54. A non-threaded second end 58 and bore 54 combination can also be employed such that second end 58 of mandrel 34 is press-fitted or friction-fitted within bore 54. Lock member 36 can be incrementally moved closer to support member 32. Accordingly, stents of any length can be securely pinched between flat ends 50 and 56 of the support and lock members 32 and 36. A stent need not, however, be pinched between ends 50 and 56; a stent can be simply crimped tightly on mandrel 34.
An embodiment of a portion of polymeric mandrel 34 is illustrated in
Polymeric mandrel 34 can be made from or coated with a biostable polymer or a bioerodable, biodegradable or bioabsorbable polymer. Bioerodable, biodegradable or bioabsorbable are intended to be used interchangeably unless otherwise indicated. In some embodiments, the polymer is the same as a polymer used to make the implantable medical device or stent 10. In some embodiments, the polymer can be different, so long as the polymer is biocompatible. If a combination of polymers is used from the device or mandrel 34, at least one of the polymers can be the same.
Representative examples of biocompatible polymers that can be used for mandrel 34 include, but are not limited to, fluorinated polymers or copolymers such as poly(vinylidene fluoride), poly(vinylidene fluoride-co-hexafluoro propene), poly(tetrafluoroethylene), and expanded poly(tetrafluoroethylene); poly(sulfone); poly(N-vinyl pyrrolidone); poly(aminocarbonates); poly(iminocarbonates); poly(anhydride-co-imides), poly(hydroxyvalerate); poly(L-lactic acid); poly(L-lactide); poly(caprolactones); poly(lactide-co-glycolide); poly(hydroxybutyrates); poly(hydroxybutyrate-co-valerate); poly(dioxanones); poly(orthoesters); poly(anhydrides); poly(glycolic acid); poly(glycolide); poly(D,L-lactic acid); poly(D,L-lactide); poly(glycolic acid-co-trimethylene carbonate); poly(phosphoesters); poly(phosphoester urethane); poly(trimethylene carbonate); poly(iminocarbonate); poly(ethylene); and any derivatives, analogs, homologues, congeners, salts, copolymers and combinations thereof.
In some embodiments, the polymers include, but are not limited to, poly(propylene) co-poly(ether-esters) such as, for example, poly(dioxanone) and poly(ethylene oxide)/poly(lactic acid); poly(anhydrides), poly(alkylene oxalates); poly(phosphazenes); poly(urethanes); silicones; poly(esters; poly(olefins); copolymers of poly(isobutylene); copolymers of ethylene-alphaolefin; vinyl halide polymers and copolymers such as poly(vinyl chloride); poly(vinyl ethers) such as, for example, poly(vinyl methyl ether); poly(vinylidene halides) such as, for example, poly(vinylidene chloride); poly(acrylonitrile); poly(vinyl ketones); poly(vinyl aromatics) such as poly(styrene); poly(vinyl esters) such as poly(vinyl acetate); copolymers of vinyl monomers and olefins such as poly(ethylene-co-vinyl alcohol) (EVAL), copolymers of acrylonitrile-styrene, ABS resins, and copolymers of ethylene-vinyl acetate; and any derivatives, analogs, homologues, congeners, salts, copolymers and combinations thereof.
In some embodiments, the polymers include, but are not limited to, poly(amides) such as Nylon 66 and poly(caprolactam); alkyd resins; poly(carbonates); poly(oxymethylenes); poly(imides); poly(ester amides); poly(ethers) including poly(alkylene glycols) such as, for example, poly(ethylene glycol) and poly(propylene glycol); epoxy resins; polyurethanes; rayon; rayon-triacetate; biomolecules such as, for example, fibrin, fibrinogen, starch, poly(amino acids); peptides, proteins, gelatin, chondroitin sulfate, dermatan sulfate (a copolymer of D-glucuronic acid or L-iduronic acid and N-acetyl-D-galactosamine), collagen, hyaluronic acid, and glycosaminoglycans; other polysaccharides such as, for example, poly(N-acetylglucosamine), chitin, chitosan, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethylcellulose; and any derivatives, analogs, homologues, congeners, salts, copolymers and combinations thereof.
In some embodiments, at least one of polymers can be a poly(ester amide), a poly(lactide) or a poly(lactide-co-glycolide) copolymer; and any derivatives, analogs, homologues, congeners, salts, copolymers and combinations thereof.
In some embodiments, the polymers can be biodegradable, bioerodable and/or bioabsorbable. Examples of biodegradable polymers include, but are not limited to, polymers having repeating units such as, for example, an a-hydroxycarboxylic acid, a cyclic diester of an α-hydroxycarboxylic acid, a dioxanone, a lactone, a cyclic carbonate, a cyclic oxalate, an epoxide, a glycol, an anhydride, a lactic acid, a glycolic acid, a lactide, a glycolide, an ethylene oxide, an ethylene glycol, and any derivatives, analogs, homologues, congeners, salts, copolymers and combinations thereof.
In some embodiments, the biodegradable polymers include, but are not limited to, polyesters, poly(ester amides); poly(hydroxyalkanoates) (PHA), amino acids; PEG and/or alcohol groups; polycaprolactones, poly(D-lactide), poly(L-lactide), poly(D,L-lactide), poly(meso-lactide), poly(L-lactide-co-meso-lactide), poly(D-lactide-co-meso-lactide), poly(D, L-lactide-co-meso-lactide), poly(D,L-lactide-co-PEG) block copolymers, poly(D,L-lactide-co-trimethylene carbonate), polyglycolides, poly(lactide-co-glycolide), polydioxanones, polyorthoesters, polyanhydrides, poly(glycolic acid-co-trimethylene carbonate), polyphosphoesters, polyphosphoester urethanes, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(imino carbonate), polycarbonates, polyurethanes, copoly(ether-esters) (e.g. PEO/PLA), polyalkylene oxalates, polyphosphazenes, PHA-PEG, and any derivatives, analogs, homologues, salts, copolymers and combinations thereof.
In other embodiments, the polymers can be poly(glycerol sebacate); tyrosine-derived polycarbonates containing desaminotyrosyl-tyrosine alkyl esters such as, for example, desaminotyrosyl-tyrosine ethyl ester (poly(DTE carbonate)); and any derivatives, analogs, homologues, salts, copolymers and combinations thereof.
In some embodiments, the polymers are selected such that they specifically exclude any one or any combination of any of the polymers taught herein.
In the manufacturing process using device 30, a polymeric tube 8 may be placed on the polymeric mandrel 34 between support member 32 and lock member 36. The polymeric tube 8 may typically be between twelve to two-hundred millimeters long depending on its intended therapeutic application. Additionally, the inner and outer surfaces of the polymeric tube 8 may vary in accordance with the intended therapeutic application and in correspondence with the outer surface of the mandrel 34. In some embodiments, the OD of the polymeric tube 8 may approximately be equivalent to the ID of the mandrel 34. In other embodiments, the OD of the polymeric tube 8 may be smaller than the ID of the mandrel 34. For example, for a polymeric tube 8 of size 0.084″ OD and 0.070″ ID, a corresponding polymer mandrel in the range of 0.025″ OD to 0.035″ OD may be used. Generally, mandrels may range in size from 0.010″ OD to 0.050″ OD, typically supplied in the sizes 0.014″ OD or 0.035″ OD.
A laser 100 may then be used for the etching process to form a polymeric stent 10 from polymeric tube 8. The laser 100 may be used in a range of fifty milliwatts to one waft, depending on the environmental conditions surrounding the laser. In contrast to the method employing device 30′, the method employing device 30 with polymeric mandrel 34 reduces the need to tailor the power from the laser 100 to the wall thickness of the polymer tube 8, thus reducing the time it takes to cut the stent 10. A typical lasing process takes approximately two minutes to twelve minutes, more particularly approximately six minutes, pursuant to a method of this invention.
In
In
The polymeric stent 10 described in
The anti-inflammatory agent can be a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, or a combination thereof. In some embodiments, anti-inflammatory drugs include, but are not limited to, alclofenac, alclometasone dipropionate, algestone acetonide, alpha amylase, amcinafal, amcinafide, amfenac sodium, amiprilose hydrochloride, anakinra, anirolac, anitrazafen, apazone, balsalazide disodium, bendazac, benoxaprofen, benzydamine hydrochloride, bromelains, broperamole, budesonide, carprofen, cicloprofen, cintazone, cliprofen, clobetasol propionate, clobetasone butyrate, clopirac, cloticasone propionate, cormethasone acetate, cortodoxone, deflazacort, desonide, desoximetasone, dexamethasone dipropionate, diclofenac potassium, diclofenac sodium, diflorasone diacetate, diflumidone sodium, diflunisal, difluprednate, diftalone, dimethyl sulfoxide, drocinonide, endrysone, enlimomab, enolicam sodium, epirizole, etodolac, etofenamate, felbinac, fenamole, fenbufen, fenclofenac, fenclorac, fendosal, fenpipalone, fentiazac, flazalone, fluazacort, flufenamic acid, flumizole, flunisolide acetate, flunixin, flunixin meglumine, fluocortin butyl, fluorometholone acetate, fluquazone, flurbiprofen, fluretofen, fluticasone propionate, furaprofen, furobufen, halcinonide, halobetasol propionate, halopredone acetate, ibufenac, ibuprofen, ibuprofen aluminum, ibuprofen piconol, ilonidap, indomethacin, indomethacin sodium, indoprofen, indoxole, intrazole, isoflupredone acetate, isoxepac, isoxicam, ketoprofen, lofemizole hydrochloride, lomoxicam, loteprednol etabonate, meclofenamate sodium, meclofenamic acid, meclorisone dibutyrate, mefenamic acid, mesalamine, meseclazone, methylprednisolone suleptanate, momiflumate, nabumetone, naproxen, naproxen sodium, naproxol, nimazone, olsalazine sodium, orgotein, orpanoxin, oxaprozin, oxyphenbutazone, paranyline hydrochloride, pentosan polysulfate sodium, phenbutazone sodium glycerate, pirfenidone, piroxicam, piroxicam cinnamate, piroxicam olamine, pirprofen, prednazate, prifelone, prodolic acid, proquazone, proxazole, proxazole citrate, rimexolone, romazarit, salcolex, salnacedin, salsalate, sanguinarium chloride, seclazone, sermetacin, sudoxicam, sulindac, suprofen, talmetacin, talniflumate, talosalate, tebufelone, tenidap, tenidap sodium, tenoxicam, tesicam, tesimide, tetrydamine, tiopinac, tixocortol pivalate, tolmetin, tolmetin sodium, triclonide, triflumidate, zidometacin, zomepirac sodium, aspirin (acetylsalicylic acid), salicylic acid, corticosteroids, glucocorticoids, tacrolimus, pimecorlimus, prodrugs thereof, co-drugs thereof, and combinations thereof.
These agents can also have anti-proliferative and/or anti-inflammmatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, antioxidant as well as cystostatic agents. Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Some other examples of other bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Examples of antineoplastics and/or antimitotics include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax ä (Biogen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), nitric oxide or nitric oxide donors, super oxide dismutases, super oxide dismutase mimetic, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), estradiol, anticancer agents, dietary supplements such as various vitamins, and a combination thereof. Examples of such cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.). An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, and genetically engineered epithelial cells. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents which are currently available or that may be developed in the future are equally applicable.
The coating method may be applied by a variety of methods, such as those disclosed in U.S. Pat. No. 6,818,063 to Kerrigan and U.S. Pat. No. 6,695,920 to Pacetti et al. In addition, the therapeutic drug may be incorporated within the polymeric tube 8 thereof, such as disclosed in U.S. Pat. No. 5,605,696 to Eury et al. Also, the polymeric tube 8 may include at least two layers of polymers with different chemical characteristics for purposes of, for example, adjusting the flexibility characteristic of the polymeric stent 10.
From the foregoing detailed description, it will be evident that there are a number of changes, adaptations and modifications of the present invention which come within the province of those skilled in the art. The scope of the invention includes any combination of the elements from the different species or embodiments disclosed herein, as well as subassemblies, assemblies, and methods thereof. However, it is intended that all such variations not departing from the spirit of the invention be considered as within the scope thereof.
Number | Name | Date | Kind |
---|---|---|---|
2072303 | Hermann et al. | Mar 1937 | A |
2386454 | Frosch et al. | Oct 1945 | A |
2845346 | Scanlon et al. | Jul 1958 | A |
3016875 | Ballentine, Jr. et al. | Jan 1962 | A |
3687135 | Stroganov et al. | Aug 1972 | A |
3773737 | Goodman et al. | Nov 1973 | A |
3827139 | Norteman | Aug 1974 | A |
3839743 | Schwarcz | Oct 1974 | A |
3849514 | Gray, Jr. et al. | Nov 1974 | A |
3882816 | Rooz et al. | May 1975 | A |
3900632 | Robinson | Aug 1975 | A |
3995075 | Cernauskas et al. | Nov 1976 | A |
4011388 | Murphy et al. | Mar 1977 | A |
4082212 | Headrick et al. | Apr 1978 | A |
4104410 | Malecki | Aug 1978 | A |
4110497 | Hoel | Aug 1978 | A |
4201149 | Koester et al. | May 1980 | A |
4226243 | Shalaby et al. | Oct 1980 | A |
4269713 | Yamashita et al. | May 1981 | A |
4290383 | Pfender | Sep 1981 | A |
4321711 | Mano | Mar 1982 | A |
4329383 | Joh | May 1982 | A |
4343931 | Barrows | Aug 1982 | A |
4346028 | Griffith | Aug 1982 | A |
4459252 | MacGregor | Jul 1984 | A |
4489670 | Mosser et al. | Dec 1984 | A |
4529792 | Barrows | Jul 1985 | A |
4560374 | Hammerslag | Dec 1985 | A |
4596574 | Urist | Jun 1986 | A |
4599085 | Riess et al. | Jul 1986 | A |
4611051 | Hayes et al. | Sep 1986 | A |
4612009 | Drobnik et al. | Sep 1986 | A |
4616593 | Kawamura et al. | Oct 1986 | A |
4629563 | Wrasidlo | Dec 1986 | A |
4633873 | Dumican et al. | Jan 1987 | A |
4640846 | Kuo | Feb 1987 | A |
4656083 | Hoffman et al. | Apr 1987 | A |
4656242 | Swan et al. | Apr 1987 | A |
4674506 | Alcond | Jun 1987 | A |
4718907 | Karwoski et al. | Jan 1988 | A |
4722335 | Vilasi | Feb 1988 | A |
4723549 | Wholey et al. | Feb 1988 | A |
4732152 | Wallstén et al. | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4740207 | Kreamer | Apr 1988 | A |
4743252 | Martin, Jr. et al. | May 1988 | A |
4762128 | Rosenbluth | Aug 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4798585 | Inoue et al. | Jan 1989 | A |
4800882 | Gianturco | Jan 1989 | A |
4816339 | Tu et al. | Mar 1989 | A |
4818559 | Hama et al. | Apr 1989 | A |
4822535 | Ekman et al. | Apr 1989 | A |
4839055 | Ishizaki et al. | Jun 1989 | A |
4846791 | Hattler et al. | Jul 1989 | A |
4850999 | Planck | Jul 1989 | A |
4865879 | Finlay | Sep 1989 | A |
4877030 | Beck et al. | Oct 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4879135 | Greco et al. | Nov 1989 | A |
4882168 | Casey et al. | Nov 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4893623 | Rosenbluth | Jan 1990 | A |
4902289 | Yannas | Feb 1990 | A |
4906423 | Frisch | Mar 1990 | A |
4931287 | Bae et al. | Jun 1990 | A |
4941870 | Okada et al. | Jul 1990 | A |
4955899 | Della Corna et al. | Sep 1990 | A |
4976736 | White et al. | Dec 1990 | A |
4977901 | Ofstead | Dec 1990 | A |
4992312 | Frisch | Feb 1991 | A |
4994298 | Yasuda | Feb 1991 | A |
5017420 | Marikar | May 1991 | A |
5019090 | Pinchuk | May 1991 | A |
5019096 | Fox, Jr. et al. | May 1991 | A |
5028597 | Kodama et al. | Jul 1991 | A |
5033405 | Yamada et al. | Jul 1991 | A |
5037392 | Hillstead | Aug 1991 | A |
5037427 | Harada et al. | Aug 1991 | A |
5059211 | Stack et al. | Oct 1991 | A |
5062829 | Pryor et al. | Nov 1991 | A |
5084065 | Weldon et al. | Jan 1992 | A |
5085629 | Goldberg et al. | Feb 1992 | A |
5095848 | Ikeno | Mar 1992 | A |
5100429 | Sinofsky et al. | Mar 1992 | A |
5100992 | Cohn et al. | Mar 1992 | A |
5104410 | Chowdhary | Apr 1992 | A |
5108417 | Sawyer | Apr 1992 | A |
5108755 | Daniels et al. | Apr 1992 | A |
5112457 | Marchant | May 1992 | A |
5123917 | Lee | Jun 1992 | A |
5133742 | Pinchuk | Jul 1992 | A |
5156623 | Hakamatsuka et al. | Oct 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5163952 | Froix | Nov 1992 | A |
5163958 | Pinchuk | Nov 1992 | A |
5165919 | Sasaki et al. | Nov 1992 | A |
5167614 | Tessmann et al. | Dec 1992 | A |
5171445 | Zepf | Dec 1992 | A |
5188734 | Zepf | Feb 1993 | A |
5192311 | King et al. | Mar 1993 | A |
5197977 | Hoffman, Jr. et al. | Mar 1993 | A |
5201314 | Bosley et al. | Apr 1993 | A |
5219980 | Swidler | Jun 1993 | A |
5229045 | Soldani | Jul 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5234457 | Andersen | Aug 1993 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5242399 | Lau et al. | Sep 1993 | A |
5258020 | Froix | Nov 1993 | A |
5264246 | Ikeno | Nov 1993 | A |
5272012 | Opolski | Dec 1993 | A |
5279594 | Jackson | Jan 1994 | A |
5282860 | Matsuno et al. | Feb 1994 | A |
5289831 | Bosley | Mar 1994 | A |
5290271 | Jernberg | Mar 1994 | A |
5292516 | Viegas et al. | Mar 1994 | A |
5298260 | Viegas et al. | Mar 1994 | A |
5300295 | Viegas et al. | Apr 1994 | A |
5306286 | Stack et al. | Apr 1994 | A |
5306294 | Winston et al. | Apr 1994 | A |
5306501 | Viegas et al. | Apr 1994 | A |
5306786 | Moens et al. | Apr 1994 | A |
5308338 | Helfrich | May 1994 | A |
5328471 | Slepian | Jul 1994 | A |
5330500 | Song | Jul 1994 | A |
5330768 | Park et al. | Jul 1994 | A |
5342348 | Kaplan | Aug 1994 | A |
5342395 | Jarrett et al. | Aug 1994 | A |
5342621 | Eury | Aug 1994 | A |
5356433 | Rowland et al. | Oct 1994 | A |
5358740 | Bornside et al. | Oct 1994 | A |
5370684 | Vallana et al. | Dec 1994 | A |
5378511 | Cardinali et al. | Jan 1995 | A |
5380299 | Fearnot et al. | Jan 1995 | A |
5383925 | Schmitt | Jan 1995 | A |
5385580 | Schmitt | Jan 1995 | A |
5389106 | Tower | Feb 1995 | A |
5399666 | Ford | Mar 1995 | A |
5417981 | Endo et al. | May 1995 | A |
5421955 | Lau et al. | Jun 1995 | A |
5423885 | Williams | Jun 1995 | A |
5441515 | Khosravi et al. | Aug 1995 | A |
5443458 | Eury et al. | Aug 1995 | A |
5443496 | Schwartz et al. | Aug 1995 | A |
5443500 | Sigwart | Aug 1995 | A |
5447724 | Helmus et al. | Sep 1995 | A |
5455040 | Marchant | Oct 1995 | A |
5458683 | Taylor et al. | Oct 1995 | A |
5462990 | Hubbell et al. | Oct 1995 | A |
5464650 | Berg et al. | Nov 1995 | A |
5485496 | Lee et al. | Jan 1996 | A |
5502158 | Sinclair et al. | Mar 1996 | A |
5514154 | Lau et al. | May 1996 | A |
5514379 | Weissleder et al. | May 1996 | A |
5516560 | Harayama et al. | May 1996 | A |
5516881 | Lee et al. | May 1996 | A |
5527337 | Stack et al. | Jun 1996 | A |
5537729 | Kolobow | Jul 1996 | A |
5538493 | Gerken et al. | Jul 1996 | A |
5545408 | Trigg et al. | Aug 1996 | A |
5554120 | Chen et al. | Sep 1996 | A |
5556413 | Lam | Sep 1996 | A |
5558900 | Fan et al. | Sep 1996 | A |
5569295 | Lam | Oct 1996 | A |
5569463 | Helmus et al. | Oct 1996 | A |
5578046 | Liu et al. | Nov 1996 | A |
5578048 | Pasqualucci et al. | Nov 1996 | A |
5578073 | Haimovich et al. | Nov 1996 | A |
5584877 | Miyake et al. | Dec 1996 | A |
5591199 | Porter et al. | Jan 1997 | A |
5591607 | Gryaznov et al. | Jan 1997 | A |
5593403 | Buscemi | Jan 1997 | A |
5593434 | Williams | Jan 1997 | A |
5599301 | Jacobs et al. | Feb 1997 | A |
5599922 | Gryaznov et al. | Feb 1997 | A |
5603721 | Lau et al. | Feb 1997 | A |
5605696 | Eury et al. | Feb 1997 | A |
5607442 | Fischell et al. | Mar 1997 | A |
5607467 | Froix | Mar 1997 | A |
5609629 | Fearnot et al. | Mar 1997 | A |
5610241 | Lee et al. | Mar 1997 | A |
5611775 | Machold et al. | Mar 1997 | A |
5616338 | Fox, Jr. et al. | Apr 1997 | A |
5618299 | Khosravi et al. | Apr 1997 | A |
5624411 | Tuch | Apr 1997 | A |
5628730 | Shapland et al. | May 1997 | A |
5628786 | Banas et al. | May 1997 | A |
5629077 | Turnlund et al. | May 1997 | A |
5631135 | Gryaznov et al. | May 1997 | A |
5632771 | Boatman et al. | May 1997 | A |
5632840 | Campbell | May 1997 | A |
5637113 | Tartaglia et al. | Jun 1997 | A |
5643580 | Subramaniam | Jul 1997 | A |
5644020 | Timmermann et al. | Jul 1997 | A |
5649977 | Campbell | Jul 1997 | A |
5656082 | Takatsuki et al. | Aug 1997 | A |
5658995 | Kohn et al. | Aug 1997 | A |
5667767 | Greff et al. | Sep 1997 | A |
5667796 | Otten | Sep 1997 | A |
5670558 | Onishi et al. | Sep 1997 | A |
5674242 | Phan et al. | Oct 1997 | A |
5679400 | Tuch | Oct 1997 | A |
5687906 | Nakagawa | Nov 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5700285 | Myers et al. | Dec 1997 | A |
5700286 | Tartaglia et al. | Dec 1997 | A |
5702754 | Zhong | Dec 1997 | A |
5707385 | Williams | Jan 1998 | A |
5711763 | Nonami et al. | Jan 1998 | A |
5711958 | Cohn et al. | Jan 1998 | A |
5713949 | Jayaraman | Feb 1998 | A |
5716981 | Hunter et al. | Feb 1998 | A |
5721131 | Rudolph et al. | Feb 1998 | A |
5723219 | Kolluri et al. | Mar 1998 | A |
5725549 | Lam | Mar 1998 | A |
5726297 | Gryaznov et al. | Mar 1998 | A |
5728751 | Patnaik | Mar 1998 | A |
5733326 | Tomonto et al. | Mar 1998 | A |
5733330 | Cox | Mar 1998 | A |
5733564 | Lehtinen | Mar 1998 | A |
5733925 | Kunz et al. | Mar 1998 | A |
5735897 | Buirge | Apr 1998 | A |
5741554 | Tisone | Apr 1998 | A |
5741881 | Patnaik | Apr 1998 | A |
5746998 | Torchilin et al. | May 1998 | A |
5756457 | Wang et al. | May 1998 | A |
5756476 | Epstein et al. | May 1998 | A |
5756553 | Iguchi et al. | May 1998 | A |
5759192 | Saunders | Jun 1998 | A |
5759205 | Valentini | Jun 1998 | A |
5765682 | Bley et al. | Jun 1998 | A |
5766204 | Porter et al. | Jun 1998 | A |
5766239 | Cox | Jun 1998 | A |
5766710 | Turnlund et al. | Jun 1998 | A |
5769883 | Buscemi et al. | Jun 1998 | A |
5772864 | Møller et al. | Jun 1998 | A |
5776184 | Tuch | Jul 1998 | A |
5780807 | Saunders | Jul 1998 | A |
5783657 | Pavlin et al. | Jul 1998 | A |
5788626 | Thompson | Aug 1998 | A |
5788979 | Alt et al. | Aug 1998 | A |
5800392 | Racchini | Sep 1998 | A |
5800516 | Fine et al. | Sep 1998 | A |
5811447 | Kunz et al. | Sep 1998 | A |
5820917 | Tuch | Oct 1998 | A |
5823996 | Sparks | Oct 1998 | A |
5824048 | Tuch | Oct 1998 | A |
5824049 | Ragheb et al. | Oct 1998 | A |
5830178 | Jones et al. | Nov 1998 | A |
5830461 | Billiar | Nov 1998 | A |
5830879 | Isner | Nov 1998 | A |
5833651 | Donovan et al. | Nov 1998 | A |
5833659 | Kranys | Nov 1998 | A |
5834582 | Sinclair et al. | Nov 1998 | A |
5836962 | Gianotti | Nov 1998 | A |
5836965 | Jendersee et al. | Nov 1998 | A |
5837008 | Berg et al. | Nov 1998 | A |
5837313 | Ding et al. | Nov 1998 | A |
5837835 | Gryaznov et al. | Nov 1998 | A |
5840083 | Braach-Maksvytis | Nov 1998 | A |
5843172 | Yan | Dec 1998 | A |
5849859 | Acemoglu | Dec 1998 | A |
5851508 | Greff et al. | Dec 1998 | A |
5853408 | Muni | Dec 1998 | A |
5854207 | Lee et al. | Dec 1998 | A |
5854376 | Higashi | Dec 1998 | A |
5855598 | Pinchuk | Jan 1999 | A |
5855600 | Alt | Jan 1999 | A |
5855612 | Ohthuki et al. | Jan 1999 | A |
5855618 | Patnaik et al. | Jan 1999 | A |
5855684 | Bergmann | Jan 1999 | A |
5858746 | Hubbell et al. | Jan 1999 | A |
5865814 | Tuch | Feb 1999 | A |
5868781 | Killion | Feb 1999 | A |
5869127 | Zhong | Feb 1999 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5874101 | Zhong et al. | Feb 1999 | A |
5874109 | Ducheyne et al. | Feb 1999 | A |
5874165 | Drumheller | Feb 1999 | A |
5876433 | Lunn | Mar 1999 | A |
5876743 | Ibsen et al. | Mar 1999 | A |
5877224 | Brocchini et al. | Mar 1999 | A |
5877263 | Patnaik et al. | Mar 1999 | A |
5879713 | Roth et al. | Mar 1999 | A |
5888533 | Dunn | Mar 1999 | A |
5891108 | Leone et al. | Apr 1999 | A |
5891192 | Murayama et al. | Apr 1999 | A |
5891507 | Jayaraman | Apr 1999 | A |
5895407 | Jayaraman | Apr 1999 | A |
5897911 | Loeffler | Apr 1999 | A |
5897955 | Drumheller | Apr 1999 | A |
5902631 | Wang et al. | May 1999 | A |
5902875 | Roby et al. | May 1999 | A |
5905168 | Dos Santos et al. | May 1999 | A |
5906759 | Richter | May 1999 | A |
5910564 | Gruning et al. | Jun 1999 | A |
5911752 | Dustrude et al. | Jun 1999 | A |
5914182 | Drumheller | Jun 1999 | A |
5914387 | Roby et al. | Jun 1999 | A |
5916870 | Lee et al. | Jun 1999 | A |
5919893 | Roby et al. | Jul 1999 | A |
5922005 | Richter et al. | Jul 1999 | A |
5922393 | Jayaraman | Jul 1999 | A |
5925720 | Kataoka et al. | Jul 1999 | A |
5928279 | Shannon et al. | Jul 1999 | A |
5932299 | Katoot | Aug 1999 | A |
5935135 | Bramfitt et al. | Aug 1999 | A |
5935506 | Schmitz et al. | Aug 1999 | A |
5942209 | Leavitt et al. | Aug 1999 | A |
5948018 | Dereume et al. | Sep 1999 | A |
5948428 | Lee et al. | Sep 1999 | A |
5954744 | Phan et al. | Sep 1999 | A |
5955509 | Webber et al. | Sep 1999 | A |
5957975 | Lafont et al. | Sep 1999 | A |
5958385 | Tondeur et al. | Sep 1999 | A |
5962138 | Kolluri et al. | Oct 1999 | A |
5965720 | Gryaznov et al. | Oct 1999 | A |
5968091 | Pinchuk et al. | Oct 1999 | A |
5971954 | Conway et al. | Oct 1999 | A |
5972027 | Johnson | Oct 1999 | A |
5976182 | Cox | Nov 1999 | A |
5980564 | Stinson | Nov 1999 | A |
5980928 | Terry | Nov 1999 | A |
5980972 | Ding | Nov 1999 | A |
5981568 | Kunz et al. | Nov 1999 | A |
5984449 | Tajika et al. | Nov 1999 | A |
5986169 | Gjunter | Nov 1999 | A |
5997468 | Wolff et al. | Dec 1999 | A |
5997517 | Whitbourne | Dec 1999 | A |
6010445 | Armini et al. | Jan 2000 | A |
6010530 | Goicoechea | Jan 2000 | A |
6010573 | Bowlin | Jan 2000 | A |
6011125 | Lohmeijer et al. | Jan 2000 | A |
6013099 | Dinh et al. | Jan 2000 | A |
6015541 | Greff et al. | Jan 2000 | A |
6030371 | Pursley | Feb 2000 | A |
6033582 | Lee et al. | Mar 2000 | A |
6034204 | Mohr et al. | Mar 2000 | A |
6042875 | Ding et al. | Mar 2000 | A |
6045899 | Wang et al. | Apr 2000 | A |
6048964 | Lee et al. | Apr 2000 | A |
6051576 | Ashton et al. | Apr 2000 | A |
6051648 | Rhee et al. | Apr 2000 | A |
6054553 | Groth et al. | Apr 2000 | A |
6056993 | Leidner et al. | May 2000 | A |
6059714 | Armini et al. | May 2000 | A |
6060451 | DiMaio et al. | May 2000 | A |
6060518 | Kabanov et al. | May 2000 | A |
6066156 | Yan | May 2000 | A |
6068202 | Hynes et al. | May 2000 | A |
6071266 | Kelley | Jun 2000 | A |
6071305 | Brown et al. | Jun 2000 | A |
6074659 | Kunz et al. | Jun 2000 | A |
6080177 | Igaki et al. | Jun 2000 | A |
6080488 | Hostettler et al. | Jun 2000 | A |
6083258 | Yadav | Jul 2000 | A |
6093463 | Thakrar | Jul 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6096525 | Patnaik | Aug 2000 | A |
6099562 | Ding et al. | Aug 2000 | A |
6103230 | Billiar et al. | Aug 2000 | A |
6106889 | Beavers et al. | Aug 2000 | A |
6107416 | Patnaik et al. | Aug 2000 | A |
6110188 | Narciso, Jr. | Aug 2000 | A |
6110483 | Whitbourne et al. | Aug 2000 | A |
6113629 | Ken | Sep 2000 | A |
6117979 | Hendriks et al. | Sep 2000 | A |
6120491 | Kohn et al. | Sep 2000 | A |
6120536 | Ding et al. | Sep 2000 | A |
6120788 | Barrows | Sep 2000 | A |
6120847 | Yang et al. | Sep 2000 | A |
6120904 | Hostettler et al. | Sep 2000 | A |
6121027 | Clapper et al. | Sep 2000 | A |
6125523 | Brown et al. | Oct 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6127173 | Eckstein et al. | Oct 2000 | A |
6129755 | Mathis et al. | Oct 2000 | A |
6129761 | Hubbell | Oct 2000 | A |
6129928 | Sarangapani et al. | Oct 2000 | A |
6136333 | Cohn et al. | Oct 2000 | A |
6140127 | Sprague | Oct 2000 | A |
6140431 | Kinker et al. | Oct 2000 | A |
6143354 | Koulik et al. | Nov 2000 | A |
6143370 | Panagiotou et al. | Nov 2000 | A |
6150630 | Perry et al. | Nov 2000 | A |
6153252 | Hossainy et al. | Nov 2000 | A |
4776337 | Palmaz | Dec 2000 | A |
6156373 | Zhong et al. | Dec 2000 | A |
6159951 | Karpeisky et al. | Dec 2000 | A |
6159978 | Myers et al. | Dec 2000 | A |
6160084 | Langer et al. | Dec 2000 | A |
6160240 | Momma et al. | Dec 2000 | A |
6165212 | Dereume et al. | Dec 2000 | A |
6165267 | Torczynski | Dec 2000 | A |
6166130 | Rhee et al. | Dec 2000 | A |
6169170 | Gryaznov et al. | Jan 2001 | B1 |
6171334 | Cox | Jan 2001 | B1 |
6171609 | Kunz | Jan 2001 | B1 |
6172167 | Stapert et al. | Jan 2001 | B1 |
6174329 | Callol et al. | Jan 2001 | B1 |
6174330 | Stinson | Jan 2001 | B1 |
6177523 | Reich et al. | Jan 2001 | B1 |
6180632 | Myers et al. | Jan 2001 | B1 |
6183505 | Mohn, Jr. et al. | Feb 2001 | B1 |
6187045 | Fehring et al. | Feb 2001 | B1 |
6194034 | Nishi et al. | Feb 2001 | B1 |
6197013 | Reed et al. | Mar 2001 | B1 |
6203551 | Wu | Mar 2001 | B1 |
6203569 | Wijay | Mar 2001 | B1 |
6206915 | Fagan et al. | Mar 2001 | B1 |
6210715 | Starling et al. | Apr 2001 | B1 |
6211249 | Cohn et al. | Apr 2001 | B1 |
6214115 | Taylor et al. | Apr 2001 | B1 |
6214901 | Chudzik et al. | Apr 2001 | B1 |
6224626 | Steinke | May 2001 | B1 |
6228072 | Omaleki et al. | May 2001 | B1 |
6228845 | Donovan et al. | May 2001 | B1 |
6231600 | Zhong | May 2001 | B1 |
6235340 | Lee et al. | May 2001 | B1 |
6240616 | Yan | Jun 2001 | B1 |
6244575 | Vaartstra et al. | Jun 2001 | B1 |
6245076 | Yan | Jun 2001 | B1 |
6245099 | Edwin et al. | Jun 2001 | B1 |
6245103 | Stinson | Jun 2001 | B1 |
6245753 | Byun et al. | Jun 2001 | B1 |
6245760 | He et al. | Jun 2001 | B1 |
6248129 | Froix | Jun 2001 | B1 |
6248344 | Ylanen et al. | Jun 2001 | B1 |
6248398 | Talieh et al. | Jun 2001 | B1 |
6251135 | Stinson et al. | Jun 2001 | B1 |
6251136 | Guruwaiya et al. | Jun 2001 | B1 |
6251142 | Bernacca et al. | Jun 2001 | B1 |
6254632 | Wu et al. | Jul 2001 | B1 |
6258121 | Yang et al. | Jul 2001 | B1 |
6258371 | Koulik et al. | Jul 2001 | B1 |
6261320 | Tam et al. | Jul 2001 | B1 |
6262034 | Mathiowitz et al. | Jul 2001 | B1 |
6270504 | Lorentzen Cornelius et al. | Aug 2001 | B1 |
6270788 | Koulik et al. | Aug 2001 | B1 |
6273878 | Muni | Aug 2001 | B1 |
6273908 | Ndondo-Lay | Aug 2001 | B1 |
6273910 | Limon | Aug 2001 | B1 |
6273913 | Wright et al. | Aug 2001 | B1 |
6277449 | Kolluri et al. | Aug 2001 | B1 |
6279368 | Escano et al. | Aug 2001 | B1 |
6281262 | Shikinami | Aug 2001 | B1 |
6283947 | Mirzaee | Sep 2001 | B1 |
6283949 | Roorda | Sep 2001 | B1 |
6284305 | Ding et al. | Sep 2001 | B1 |
6284333 | Wang et al. | Sep 2001 | B1 |
6287249 | Tam et al. | Sep 2001 | B1 |
6287332 | Bolz et al. | Sep 2001 | B1 |
6287628 | Hossainy et al. | Sep 2001 | B1 |
6290721 | Heath | Sep 2001 | B1 |
6293966 | Frantzen | Sep 2001 | B1 |
6299604 | Ragheb et al. | Oct 2001 | B1 |
6303901 | Perry et al. | Oct 2001 | B1 |
6306165 | Patnaik et al. | Oct 2001 | B1 |
6306176 | Whitbourne | Oct 2001 | B1 |
6312459 | Huang et al. | Nov 2001 | B1 |
6322847 | Zhong et al. | Nov 2001 | B1 |
6327772 | Zadno-Azizi et al. | Dec 2001 | B1 |
6331191 | Chobotov | Dec 2001 | B1 |
6331313 | Wong et al. | Dec 2001 | B1 |
4733665 | Palmaz | Jan 2002 | C2 |
6335029 | Kamath et al. | Jan 2002 | B1 |
6344035 | Chudzik et al. | Feb 2002 | B1 |
6346110 | Wu | Feb 2002 | B2 |
6358556 | Ding et al. | Mar 2002 | B1 |
6358567 | Pham et al. | Mar 2002 | B2 |
6364903 | Tseng et al. | Apr 2002 | B2 |
6368658 | Schwarz et al. | Apr 2002 | B1 |
6372283 | Shim et al. | Apr 2002 | B1 |
6375826 | Wang et al. | Apr 2002 | B1 |
6379381 | Hossainy et al. | Apr 2002 | B1 |
6383215 | Sass | May 2002 | B1 |
6387118 | Hanson | May 2002 | B1 |
6387121 | Alt | May 2002 | B1 |
6387379 | Goldberg et al. | May 2002 | B1 |
6388043 | Langer et al. | May 2002 | B1 |
6395326 | Castro et al. | May 2002 | B1 |
6407009 | You et al. | Jun 2002 | B1 |
6409761 | Jang | Jun 2002 | B1 |
6416543 | Hilaire et al. | Jul 2002 | B1 |
6419692 | Yang et al. | Jul 2002 | B1 |
6423092 | Datta et al. | Jul 2002 | B2 |
6435798 | Satoh | Aug 2002 | B1 |
6440221 | Shamouilian et al. | Aug 2002 | B2 |
6451373 | Hossainy et al. | Sep 2002 | B1 |
6461632 | Gogolewski | Oct 2002 | B1 |
6464720 | Boatman et al. | Oct 2002 | B2 |
6475779 | Mathiowitz et al. | Nov 2002 | B2 |
6479565 | Stanley | Nov 2002 | B1 |
6482834 | Spada et al. | Nov 2002 | B2 |
6485512 | Cheng | Nov 2002 | B1 |
6492615 | Flanagan | Dec 2002 | B1 |
6494862 | Ray et al. | Dec 2002 | B1 |
6494908 | Huxel et al. | Dec 2002 | B1 |
6495156 | Wenz et al. | Dec 2002 | B2 |
6503538 | Chu et al. | Jan 2003 | B1 |
6503556 | Harish et al. | Jan 2003 | B2 |
6503954 | Bhat et al. | Jan 2003 | B1 |
6506437 | Harish et al. | Jan 2003 | B1 |
6511748 | Barrows | Jan 2003 | B1 |
6517534 | McGovern et al. | Feb 2003 | B1 |
6517888 | Weber | Feb 2003 | B1 |
6517889 | Jayaraman | Feb 2003 | B1 |
6521284 | Parsons et al. | Feb 2003 | B1 |
6524347 | Myers et al. | Feb 2003 | B1 |
6527801 | Dutta | Mar 2003 | B1 |
6527863 | Pacetti et al. | Mar 2003 | B1 |
6528526 | Myers et al. | Mar 2003 | B1 |
6530950 | Alvarado et al. | Mar 2003 | B1 |
6530951 | Bates et al. | Mar 2003 | B1 |
6534112 | Bouchier et al. | Mar 2003 | B1 |
6537589 | Chae et al. | Mar 2003 | B1 |
6539607 | Fehring et al. | Apr 2003 | B1 |
6540776 | Sanders Millare et al. | Apr 2003 | B2 |
6540777 | Stenzel | Apr 2003 | B2 |
6544223 | Kokish | Apr 2003 | B1 |
6544543 | Mandrusov et al. | Apr 2003 | B1 |
6544582 | Yoe | Apr 2003 | B1 |
6554854 | Flanagan | Apr 2003 | B1 |
6555157 | Hossainy | Apr 2003 | B1 |
6558733 | Hossainy et al. | May 2003 | B1 |
6562136 | Chappa et al. | May 2003 | B1 |
6565599 | Hong et al. | May 2003 | B1 |
6565659 | Pacetti et al. | May 2003 | B1 |
6569191 | Hogan | May 2003 | B1 |
6569193 | Cox et al. | May 2003 | B1 |
6572644 | Moein | Jun 2003 | B1 |
6572651 | De Scheerder et al. | Jun 2003 | B1 |
6572672 | Yadav et al. | Jun 2003 | B2 |
6574851 | Mirizzi | Jun 2003 | B1 |
6575933 | Wittenberger et al. | Jun 2003 | B1 |
6585755 | Jackson et al. | Jul 2003 | B2 |
6585765 | Hossainy et al. | Jul 2003 | B1 |
6585926 | Mirzaee | Jul 2003 | B1 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6592617 | Thompson | Jul 2003 | B2 |
6605154 | Villareal | Aug 2003 | B1 |
6610087 | Zarbatany et al. | Aug 2003 | B1 |
6613072 | Lau et al. | Sep 2003 | B2 |
6613432 | Zamora et al. | Sep 2003 | B2 |
6616765 | Hossainy et al. | Sep 2003 | B1 |
6620617 | Mathiowitz et al. | Sep 2003 | B2 |
6623448 | Slater | Sep 2003 | B2 |
6625486 | Lundkvist et al. | Sep 2003 | B2 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6635269 | Jennissen | Oct 2003 | B1 |
6641611 | Jayaraman | Nov 2003 | B2 |
6645135 | Bhat | Nov 2003 | B1 |
6645195 | Bhat et al. | Nov 2003 | B1 |
6645243 | Vallana et al. | Nov 2003 | B2 |
6656162 | Santini, Jr. et al. | Dec 2003 | B2 |
6656216 | Hossainy et al. | Dec 2003 | B1 |
6656506 | Wu et al. | Dec 2003 | B1 |
6660034 | Mandrusov et al. | Dec 2003 | B1 |
6663662 | Pacetti et al. | Dec 2003 | B2 |
6663880 | Roorda et al. | Dec 2003 | B1 |
6664335 | Krishnan | Dec 2003 | B2 |
6666214 | Canham | Dec 2003 | B2 |
6666880 | Chiu et al. | Dec 2003 | B1 |
6667049 | Janas et al. | Dec 2003 | B2 |
6669723 | Killion et al. | Dec 2003 | B2 |
6673154 | Pacetti et al. | Jan 2004 | B1 |
6673385 | Ding et al. | Jan 2004 | B1 |
6676697 | Richter | Jan 2004 | B1 |
6676700 | Jacobs et al. | Jan 2004 | B1 |
6679980 | Andreacchi | Jan 2004 | B1 |
6682771 | Zhong et al. | Jan 2004 | B2 |
6689099 | Mirzaee | Feb 2004 | B2 |
6689350 | Uhrich | Feb 2004 | B2 |
6689375 | Wahlig et al. | Feb 2004 | B1 |
6695920 | Pacetti et al. | Feb 2004 | B1 |
6706013 | Bhat et al. | Mar 2004 | B1 |
6706273 | Roessler | Mar 2004 | B1 |
6709379 | Brandau et al. | Mar 2004 | B1 |
6709514 | Hossainy | Mar 2004 | B1 |
6712845 | Hossainy | Mar 2004 | B2 |
6713119 | Hossainy et al. | Mar 2004 | B2 |
6716444 | Castro et al. | Apr 2004 | B1 |
6719934 | Stinson | Apr 2004 | B2 |
6719989 | Matsushima et al. | Apr 2004 | B1 |
6720402 | Langer et al. | Apr 2004 | B2 |
6723120 | Yan | Apr 2004 | B2 |
6723373 | Narayanan et al. | Apr 2004 | B1 |
6730064 | Ragheb et al. | May 2004 | B2 |
6733768 | Hossainy et al. | May 2004 | B2 |
6740040 | Mandrusov et al. | May 2004 | B1 |
6743462 | Pacetti | Jun 2004 | B1 |
6746773 | Llanos et al. | Jun 2004 | B2 |
6749626 | Bhat et al. | Jun 2004 | B1 |
6752826 | Holloway et al. | Jun 2004 | B2 |
6753007 | Haggard et al. | Jun 2004 | B2 |
6753071 | Pacetti et al. | Jun 2004 | B1 |
6758859 | Dang et al. | Jul 2004 | B1 |
6759054 | Chen et al. | Jul 2004 | B2 |
6764505 | Hossainy et al. | Jul 2004 | B1 |
6776796 | Falotico et al. | Aug 2004 | B2 |
6780424 | Claude | Aug 2004 | B2 |
6790228 | Hossainy et al. | Sep 2004 | B2 |
6818063 | Kerrigan | Nov 2004 | B1 |
6824559 | Michal | Nov 2004 | B2 |
6846323 | Yip et al. | Jan 2005 | B2 |
6860946 | Hossainy et al. | Mar 2005 | B2 |
6887510 | Villareal | May 2005 | B2 |
6890583 | Chudzik et al. | May 2005 | B2 |
6955723 | Pacetti et al. | Oct 2005 | B2 |
20010007083 | Roorda | Jul 2001 | A1 |
20010029351 | Falotico et al. | Oct 2001 | A1 |
20010037145 | Guruwaiya et al. | Nov 2001 | A1 |
20010044652 | Moore | Nov 2001 | A1 |
20020002399 | Huxel et al. | Jan 2002 | A1 |
20020004060 | Heublein et al. | Jan 2002 | A1 |
20020004101 | Ding et al. | Jan 2002 | A1 |
20020005206 | Falotico et al. | Jan 2002 | A1 |
20020007213 | Falotico et al. | Jan 2002 | A1 |
20020007214 | Falotico | Jan 2002 | A1 |
20020007215 | Falotico et al. | Jan 2002 | A1 |
20020038767 | Trozera | Apr 2002 | A1 |
20020050220 | Schueller et al. | May 2002 | A1 |
20020051730 | Bodnar et al. | May 2002 | A1 |
20020062148 | Hart | May 2002 | A1 |
20020065553 | Weber | May 2002 | A1 |
20020077693 | Barclay et al. | Jun 2002 | A1 |
20020082679 | Sirhan et al. | Jun 2002 | A1 |
20020087123 | Hossainy et al. | Jul 2002 | A1 |
20020091433 | Ding et al. | Jul 2002 | A1 |
20020111590 | Davila et al. | Aug 2002 | A1 |
20020116050 | Kocur | Aug 2002 | A1 |
20020138133 | Lenz et al. | Sep 2002 | A1 |
20020161114 | Gunatillake et al. | Oct 2002 | A1 |
20020165608 | Llanos et al. | Nov 2002 | A1 |
20020176849 | Slepian | Nov 2002 | A1 |
20020183581 | Yoe et al. | Dec 2002 | A1 |
20020188037 | Chudzik et al. | Dec 2002 | A1 |
20020188277 | Roorda et al. | Dec 2002 | A1 |
20030004141 | Brown | Jan 2003 | A1 |
20030028243 | Bates et al. | Feb 2003 | A1 |
20030028244 | Bates et al. | Feb 2003 | A1 |
20030031780 | Chudzik et al. | Feb 2003 | A1 |
20030032767 | Tada et al. | Feb 2003 | A1 |
20030033001 | Igaki | Feb 2003 | A1 |
20030036794 | Ragheb et al. | Feb 2003 | A1 |
20030039689 | Chen et al. | Feb 2003 | A1 |
20030040712 | Ray et al. | Feb 2003 | A1 |
20030040790 | Furst | Feb 2003 | A1 |
20030059520 | Chen et al. | Mar 2003 | A1 |
20030060877 | Falotico et al. | Mar 2003 | A1 |
20030065377 | Davila et al. | Apr 2003 | A1 |
20030069629 | Jadhav et al. | Apr 2003 | A1 |
20030072868 | Harish et al. | Apr 2003 | A1 |
20030073961 | Happ | Apr 2003 | A1 |
20030083646 | Sirhan et al. | May 2003 | A1 |
20030083739 | Cafferata | May 2003 | A1 |
20030088307 | Shulze et al. | May 2003 | A1 |
20030093107 | Parsonage et al. | May 2003 | A1 |
20030097088 | Pacetti | May 2003 | A1 |
20030097173 | Dutta | May 2003 | A1 |
20030100865 | Santini, Jr. et al. | May 2003 | A1 |
20030105518 | Dutta | Jun 2003 | A1 |
20030105530 | Pirhonen | Jun 2003 | A1 |
20030113439 | Pacetti et al. | Jun 2003 | A1 |
20030150380 | Yoe | Aug 2003 | A1 |
20030158517 | Kokish | Aug 2003 | A1 |
20030171053 | Sanders | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030190406 | Hossainy et al. | Oct 2003 | A1 |
20030208259 | Penhasi | Nov 2003 | A1 |
20030209835 | Chun et al. | Nov 2003 | A1 |
20030211230 | Pacetti et al. | Nov 2003 | A1 |
20030215564 | Heller et al. | Nov 2003 | A1 |
20030226833 | Shapovalov et al. | Dec 2003 | A1 |
20030236563 | Fifer | Dec 2003 | A1 |
20040018296 | Castro et al. | Jan 2004 | A1 |
20040029952 | Chen et al. | Feb 2004 | A1 |
20040047978 | Hossainy et al. | Mar 2004 | A1 |
20040047980 | Pacetti et al. | Mar 2004 | A1 |
20040052858 | Wu et al. | Mar 2004 | A1 |
20040052859 | Wu et al. | Mar 2004 | A1 |
20040054104 | Pacetti | Mar 2004 | A1 |
20040060508 | Pacetti et al. | Apr 2004 | A1 |
20040062853 | Pacetti et al. | Apr 2004 | A1 |
20040063805 | Pacetti et al. | Apr 2004 | A1 |
20040071861 | Mandrusov et al. | Apr 2004 | A1 |
20040072922 | Hossainy et al. | Apr 2004 | A1 |
20040073298 | Hossainy | Apr 2004 | A1 |
20040086542 | Hossainy et al. | May 2004 | A1 |
20040086550 | Roorda et al. | May 2004 | A1 |
20040093077 | White et al. | May 2004 | A1 |
20040096504 | Michal | May 2004 | A1 |
20040098095 | Burnside et al. | May 2004 | A1 |
20040098117 | Hossainy et al. | May 2004 | A1 |
20040111149 | Stinson | Jun 2004 | A1 |
20040127970 | Saunders et al. | Jul 2004 | A1 |
20040143317 | Stinson et al. | Jul 2004 | A1 |
20040167610 | Fleming, III | Aug 2004 | A1 |
20040191405 | Kerrigan | Sep 2004 | A1 |
20040213893 | Boulais | Oct 2004 | A1 |
20040232120 | Wessner | Nov 2004 | A1 |
20050069630 | Fox et al. | Mar 2005 | A1 |
20050074544 | Pacetti et al. | Apr 2005 | A1 |
Number | Date | Country |
---|---|---|
42 24 401 | Jan 1994 | DE |
44 07 079 | Sep 1994 | DE |
197 31 021 | Jan 1999 | DE |
198 56 983 | Dec 1999 | DE |
199 01 530 | Jul 2000 | DE |
0 108 171 | May 1984 | EP |
0 144 534 | Jun 1985 | EP |
0 301 856 | Feb 1989 | EP |
0 364 787 | Apr 1990 | EP |
0 396 429 | Nov 1990 | EP |
0 397 500 | Nov 1990 | EP |
0 464 755 | Jan 1992 | EP |
0 493 788 | Jul 1992 | EP |
0 514 406 | Nov 1992 | EP |
0 554 082 | Aug 1993 | EP |
0 578 998 | Jan 1994 | EP |
0 604 022 | Jun 1994 | EP |
0 621 017 | Oct 1994 | EP |
0 623 354 | Nov 1994 | EP |
0 627 226 | Dec 1994 | EP |
0 665 023 | Aug 1995 | EP |
0 701 802 | Mar 1996 | EP |
0 709 068 | May 1996 | EP |
0 716 836 | Jun 1996 | EP |
0 809 999 | Dec 1997 | EP |
0 832 655 | Apr 1998 | EP |
0 850 651 | Jul 1998 | EP |
0 875 218 | Nov 1998 | EP |
0 879 595 | Nov 1998 | EP |
0 897 701 | Feb 1999 | EP |
0 910 584 | Apr 1999 | EP |
0 923 953 | Jun 1999 | EP |
0 953 320 | Nov 1999 | EP |
0 970 711 | Jan 2000 | EP |
0 982 041 | Mar 2000 | EP |
1 023 879 | Aug 2000 | EP |
1 192 957 | Apr 2002 | EP |
1 273 314 | Jan 2003 | EP |
2 247 696 | Mar 1992 | GB |
05009726 | Jan 1993 | JP |
11299901 | Nov 1999 | JP |
2001-190687 | Jul 2001 | JP |
872531 | Oct 1981 | SU |
876663 | Oct 1981 | SU |
905228 | Feb 1982 | SU |
790725 | Feb 1983 | SU |
1016314 | May 1983 | SU |
811750 | Sep 1983 | SU |
1293518 | Feb 1987 | SU |
WO 8903232 | Apr 1989 | WO |
WO 9001969 | Mar 1990 | WO |
WO 9004982 | May 1990 | WO |
WO 9006094 | Jun 1990 | WO |
WO 9112846 | Sep 1991 | WO |
WO 9117744 | Nov 1991 | WO |
WO 9117789 | Nov 1991 | WO |
WO 9210218 | Jun 1992 | WO |
WO 9306792 | Apr 1993 | WO |
WO 9409760 | May 1994 | WO |
WO 9421196 | Sep 1994 | WO |
WO 9510989 | Apr 1995 | WO |
WO 9524929 | Sep 1995 | WO |
WO 9529647 | Nov 1995 | WO |
WO 9640174 | Dec 1996 | WO |
WO 9710011 | Mar 1997 | WO |
WO 9745105 | Dec 1997 | WO |
WO 9746590 | Dec 1997 | WO |
WO 9804415 | Feb 1998 | WO |
WO 9808463 | Mar 1998 | WO |
WO 9817331 | Apr 1998 | WO |
WO 9823228 | Jun 1998 | WO |
WO 9832398 | Jul 1998 | WO |
WO 9836784 | Aug 1998 | WO |
WO 9901118 | Jan 1999 | WO |
WO 9903515 | Jan 1999 | WO |
WO 9916386 | Apr 1999 | WO |
WO 9938546 | Aug 1999 | WO |
WO 9942147 | Aug 1999 | WO |
WO 9963981 | Dec 1999 | WO |
WO 0002599 | Jan 2000 | WO |
WO 0012147 | Mar 2000 | WO |
WO 0018446 | Apr 2000 | WO |
WO 0064506 | Nov 2000 | WO |
WO 0100112 | Jan 2001 | WO |
WO 0101890 | Jan 2001 | WO |
WO 0115751 | Mar 2001 | WO |
WO 0117577 | Mar 2001 | WO |
WO 0145763 | Jun 2001 | WO |
WO 0149338 | Jul 2001 | WO |
WO 0151027 | Jul 2001 | WO |
WO 0152772 | Jul 2001 | WO |
WO 0174414 | Oct 2001 | WO |
WO 0191918 | Dec 2001 | WO |
WO 0203890 | Jan 2002 | WO |
WO 0226162 | Apr 2002 | WO |
WO 0234311 | May 2002 | WO |
WO 02056790 | Jul 2002 | WO |
WO 02058753 | Aug 2002 | WO |
WO 02102283 | Dec 2002 | WO |
WO 03000308 | Jan 2003 | WO |
WO 03022323 | Mar 2003 | WO |
WO 03028780 | Apr 2003 | WO |
WO 03037223 | May 2003 | WO |
WO 03039612 | May 2003 | WO |
WO 03080147 | Oct 2003 | WO |
WO 03082368 | Oct 2003 | WO |
WO 2004000383 | Dec 2003 | WO |
WO 2004009145 | Jan 2004 | WO |
WO 2004023985 | Mar 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20060287715 A1 | Dec 2006 | US |